Market assessment for innovative functional food products

创新功能食品的市场评估

• 批准号: 700039
• 金额: $ 3.19万
• 依托单位: VHSQUARED LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700039
• 关键词: Market; assessment; innovative; functional; food

This project addresses the need to understand the market opportunities that are made possibleby a new antibody technology being developed by VHsquared. The technology enables costeffective development and production of VHH domain fragment antibodies that areengineered to resist the effects of digestion. This opens up the opportunity to include specificantibody-like fragments as ingredients in food products or their use as dietary additives andsupplements, as well as orally-delivered pharmaceutical agents. Antibodies that are usedmedically have become multi-billion pound products and represent the fastest growing classof therapeutic molecule in the pharmaceutical sector. To date, however, antibodies have beenlimited by the need for their administration by direct injection, the high cost of theirproduction, and their sensitivity to degradation when administered orally. The VHsquaredtechnology is set to change this and shift the use of antibody technology from the lowvolume/high cost pharmaceutical sector towards the higher volume/lower cost end occupiedby functional and medical food and lower cost pharmaceutical products. This willdramatically expand the utility of antibodies and create a raft of new opportunities. Thisproject seeks to map the way forward for VHsquared’s first products by creating a betterunderstanding of the market dynamics, competitive forces and prevailing regulatoryconstraints.

该项目解决了了解 VHsquared 正在开发的新抗体技术所带来的市场机会的需求，该技术能够以经济高效的方式开发和生产经设计可抵抗消化影响的 VHH 结构域片段抗体。将特定抗体样片段作为食品成分或将其用作膳食添加剂和补充剂的机会，以及医学上使用的口服药物制剂已成为价值数十亿英镑的产品，代表了增长最快的产品。然而，迄今为止，抗体一直受到直接注射给药的需要、生产成本高以及口服给药时对降解的敏感性的限制。并将抗体技术的使用从低产量/高成本的制药领域转向功能性和医用食品以及低成本药品所占据的高产量/低成本领域，这将极大地扩大抗体的效用并创造大量新的产品。该项目寻求机会。通过更好地了解市场动态、竞争力量和现行监管限制，为 VHsquared 的首批产品规划未来发展方向。